NO20011891L - Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon - Google Patents
Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjonInfo
- Publication number
- NO20011891L NO20011891L NO20011891A NO20011891A NO20011891L NO 20011891 L NO20011891 L NO 20011891L NO 20011891 A NO20011891 A NO 20011891A NO 20011891 A NO20011891 A NO 20011891A NO 20011891 L NO20011891 L NO 20011891L
- Authority
- NO
- Norway
- Prior art keywords
- beta
- inhibitors
- screening
- amyloid
- radioligands
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000002287 radioligand Substances 0.000 title 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10814798P | 1998-11-12 | 1998-11-12 | |
| US13128499P | 1999-04-27 | 1999-04-27 | |
| PCT/US1999/026715 WO2000028331A1 (en) | 1998-11-12 | 1999-11-12 | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20011891D0 NO20011891D0 (no) | 2001-04-17 |
| NO20011891L true NO20011891L (no) | 2001-07-02 |
Family
ID=26805566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011891A NO20011891L (no) | 1998-11-12 | 2001-04-17 | Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6331408B1 (de) |
| EP (1) | EP1129355B1 (de) |
| AT (1) | ATE300052T1 (de) |
| AU (1) | AU1618000A (de) |
| CA (1) | CA2346099A1 (de) |
| DE (1) | DE69926254D1 (de) |
| NO (1) | NO20011891L (de) |
| WO (1) | WO2000028331A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
| US6737038B1 (en) * | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| AU1618000A (en) * | 1998-11-12 | 2000-05-29 | Du Pont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
| EP1313426A2 (de) | 1998-12-24 | 2003-05-28 | Bristol-Myers Squibb Pharma Company | Succinoylaminobenzodiazepine als inhibitoren der a-beta proteinproduktion |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| US6525044B2 (en) | 2000-02-17 | 2003-02-25 | Bristol-Myers Squibb Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production |
| CN1436175A (zh) | 2000-04-03 | 2003-08-13 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ-蛋白生产抑制剂的环状内酰胺 |
| JP2004508289A (ja) | 2000-04-03 | 2004-03-18 | デュポン ファーマシューティカルズ カンパニー | Aβタンパク質産生の阻害剤としての環状ラクタム |
| US6878363B2 (en) * | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| EP1268450A1 (de) * | 2000-06-01 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Durch bernsteinsäurediamid substituierte lactamverbindungen als a-beta-protein-produktionsinhibitoren |
| JP2004535560A (ja) * | 2001-04-20 | 2004-11-25 | ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション, インク. | 活性部位不活性化因子 |
| US20090062256A1 (en) * | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
| US7906625B2 (en) * | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| WO2009085200A2 (en) | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
| WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| EP2897960B1 (de) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclische/heterocyclische verbindungen als notch-inhibitoren |
| WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
| WO2014047391A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
| EP2897954B1 (de) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoralkyl-1,4-benzodiazepinon-verbindungen |
| TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
| EP2897947B1 (de) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1, 4-benzodiazepinonverbindungen |
| WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| US9242940B2 (en) | 2012-09-21 | 2016-01-26 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
| WO2014165718A1 (en) | 2013-04-04 | 2014-10-09 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
| US5252463A (en) * | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
| GB9022117D0 (en) * | 1990-10-11 | 1990-11-21 | Beecham Group Plc | Novel compounds |
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US5538845A (en) * | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| US5594006A (en) * | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
| WO1994026723A2 (en) * | 1993-05-14 | 1994-11-24 | Genentech, Inc. | ras FARNESYL TRANSFERASE INHIBITORS |
| NZ264143A (en) * | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
| US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
| US5942400A (en) * | 1995-06-07 | 1999-08-24 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase |
| US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
| WO1998015828A1 (en) * | 1996-10-07 | 1998-04-16 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
| US5734054A (en) * | 1996-11-05 | 1998-03-31 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
| AU1618000A (en) * | 1998-11-12 | 2000-05-29 | Du Pont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
-
1999
- 1999-11-12 AU AU16180/00A patent/AU1618000A/en not_active Abandoned
- 1999-11-12 CA CA002346099A patent/CA2346099A1/en not_active Abandoned
- 1999-11-12 AT AT99958905T patent/ATE300052T1/de not_active IP Right Cessation
- 1999-11-12 WO PCT/US1999/026715 patent/WO2000028331A1/en not_active Ceased
- 1999-11-12 DE DE69926254T patent/DE69926254D1/de not_active Expired - Lifetime
- 1999-11-12 EP EP99958905A patent/EP1129355B1/de not_active Expired - Lifetime
- 1999-11-12 US US09/438,901 patent/US6331408B1/en not_active Expired - Lifetime
-
2001
- 2001-04-17 NO NO20011891A patent/NO20011891L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1129355B1 (de) | 2005-07-20 |
| DE69926254D1 (de) | 2005-08-25 |
| CA2346099A1 (en) | 2000-05-18 |
| NO20011891D0 (no) | 2001-04-17 |
| US6331408B1 (en) | 2001-12-18 |
| EP1129355A1 (de) | 2001-09-05 |
| WO2000028331A1 (en) | 2000-05-18 |
| ATE300052T1 (de) | 2005-08-15 |
| AU1618000A (en) | 2000-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20011891D0 (no) | Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon | |
| DE69429527D1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| DE69432629D1 (de) | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung | |
| WO2001087354A3 (en) | Use of small molecule radioligands for diagnostic imaging | |
| WO2003042654A3 (en) | Multi-parameter high throughput screening assays (mphts) | |
| WO2003104418A3 (en) | Reconstituted polypeptides | |
| GB0117326D0 (en) | Napthoquinone-type inhibitors of protein aggregation | |
| WO2005018424A3 (en) | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits | |
| MXPA05003621A (es) | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| EA200400699A1 (ru) | 3,4-дизамещенные, 3,5-дизамещенные и 3,4,5-замещенные пиперидины и пиперазины | |
| NO20063196L (no) | Nye fusjonerte pyrrolokarbazoler | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| ATE522230T1 (de) | Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit | |
| DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| IL169889A0 (en) | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| MY120085A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines. | |
| WO2004005882A3 (en) | Multi-parameter high throughput screening assays (mphts) | |
| TW200504036A (en) | Novel lactams and uses thereof | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| WO2001049871A3 (en) | Process for finding a protease inhibitor | |
| WO2004047854A3 (en) | Methods for the treatment of alzheimers disease and compositions therefore | |
| WO1999006838A3 (en) | Novel method of detecting amyloid-like fibrils or protein aggregates | |
| ATE420637T1 (de) | Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |